Trial Profile
RSV-Neutralizing Serum Antibody Levels in high risk children following 3 to 4 doses of Palivizumab compared to healthy controls (Adults + Children)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacodynamics
- 18 Aug 2015 New trial record